Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	ILA 270.50	+1.39%	6,258
26-07-02	ILA 266.80	-2.09%	49,297
26-07-01	ILA 272.50	-0.22%	4,539
26-06-30	ILA 273.10	-1.90%	45,210
26-06-29	ILA 278.40	-2.28%	12,071

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 06:44:07 2026-07-03 EDT			5-day change	1st Jan Change
270.50 ^ILa	+1.39%		-6.88%	-50.90%

06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI

Market Cap	79.11M 7.91B 26.41M 23.1M 21.2M 19.76M 37.46M 2.51B 38.06M 255M 99M 1.23B 99.16M 96.99M 4.26B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	58.97M 5.9B 19.69M 17.22M 15.8M 14.73M 27.92M 1.87B 28.37M 190M 73.8M 920M 73.91M 72.3M 3.18B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-23	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
25-08-03	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-11	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
02-27	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR
02-26	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation	PR

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.39%
1 week	-6.88%
Current month	-0.95%
1 month	-4.11%
3 months	-19.85%
6 months	-52.96%
Current year	-50.90%

1 week	260	289.8
1 month	248	326
Current year	212	853
1 year	204	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	53	2019-05-31
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	2019-05-31
Alon Sinai COO	Chief Operating Officer	58	2019-06-30

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	58	2019-06-30
Tal Dvir BRD	Director/Board Member	51	2019-05-31
Stanley Hirsch BRD	Director/Board Member	68	2022-07-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+1.39%	-6.88%	+17.66%	-35.49%	26.05M
LONZA GROUP AG	+1.70%	+6.89%	+2.76%	+7.65%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+6.21%	+408.85%	+607.44%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+11.06%	+25.75%	-7.89%	34.55B
BEONE MEDICINES AG	+2.38%	+8.10%	+21.83%	+66.94%	33.09B
CELLTRION, INC.	+3.96%	+6.07%	+14.14%	+37.68%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+4.94%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+7.24%	+71.03%	+132.17%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+1.58%	+14.34%	+19.26%	13.83B
ICON PUBLIC LIMITED COMPANY	-1.14%	+7.52%	+14.75%	-30.83%	13.26B
Average	+1.65%	+4.57%	+65.68%	+88.55%	24.23B
Weighted average by Cap.	+1.81%	+6.31%	+89.14%	+131.71%

	2024	2025
Net sales	-	-
Net income	-15.58M -1.56B -5.2M -4.55M -4.18M -3.89M -7.38M -495M -7.5M -50.17M -19.5M -243M -19.53M -19.11M -839M	-27.82M -2.78B -9.29M -8.12M -7.46M -6.95M -13.17M -884M -13.38M -89.58M -34.82M -434M -34.87M -34.11M -1.5B
Net Debt	-10.68M -1.07B -3.57M -3.12M -2.86M -2.67M -5.06M -339M -5.14M -34.39M -13.37M -167M -13.39M -13.09M -575M	-20.14M -2.01B -6.72M -5.88M -5.4M -5.03M -9.54M -640M -9.69M -64.85M -25.21M -314M -25.24M -24.69M -1.08B